CompletedPhase 3NCT01282268
Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Studying Fragile X syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seaside Therapeutics, Inc.
- Principal Investigator
- Paul Wang, M.D.Seaside Therapeutics, Inc.
- Intervention
- arbaclofen(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 12-50 years · All sexes
- Timeline
- 2011
Study locations (24)
- Southwest Autism Research & Resource Center, Phoenix, Arizona, United States
- Miller Children's Hospital Research Administration, Long Beach, California, United States
- University of California-Davis, M.I.N.D. Institute, Sacramento, California, United States
- Psychiatric Centers at San Diego, San Diego, California, United States
- University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States
- University of Miami, Mailman Center for Child Development, Miami, Florida, United States
- Lake Mary Pediatrics, Orange City, Florida, United States
- Emory University School of Medicine, Decatur, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- University of Massachusetts, Worcester, Massachusetts, United States
- University of Missouri, Thompson Research Center for Autism & Neurodevelpmental Disorders, Columbia, Missouri, United States
- Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States
- New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01282268 on ClinicalTrials.govOther trials for Fragile X syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07493096Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal DisordersHealing Hope International
- RECRUITINGPHASE2NCT07209462Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)Mirum Pharmaceuticals, Inc.
- RECRUITINGNANCT06868979Optical Imaging in X-linked Disorders.Hospices Civils de Lyon
- RECRUITINGNANCT06740162Physical Activity and Community EmPOWERment ProjectUniversity of North Carolina, Chapel Hill
- RECRUITINGPHASE2NCT06081348Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental DisordersHolland Bloorview Kids Rehabilitation Hospital
- RECRUITINGNANCT06279858Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X SyndromeSpecila hospital for cerebral palsy and developmental neurology
- RECRUITINGNANCT06088589Speech-in-noise Perception in Autism and Fragile XChildren's Hospital Medical Center, Cincinnati
- RECRUITINGNANCT06139172Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)Rush University Medical Center